检索结果-南通市图书馆

Cardio-Toxicity during chemotherapy: feasibility of new diagnostic approaches

Health 2010年第4期2卷 376-380页

作者： fable zustovich Mario Trivellato Renato Ceravolo Davide Pastorelli Rosanna Canton Lorena Buratin Monica Mion Martina Zaninotto Martina Mattiazzi Mario Plebani Giuseppe Cartei 不详

Chemotherapy induced cardio-toxicity is a well known side effect of anticancer treatments, moreover the 70% of all tumors involve patients over 65 years-old, frequently with cardiac co- morbidity. We evaluated the feasibility of the application during chemotherapy administration of some of the most recent diagnostic techniques as 12-diagnostic leads telemetry, 7 days EKG monitoring device (R-Test Evolution 3R), blood level dosage of Brain Natriuretic Peptide (BNP) and Ischemia Modified Albumin (IMA). Some sub-clinical changes in the investigated parameters were found in patients undergoing chemotherapy, mostly containing fluorouracil, as shown in the following paper. Far from suggesting a widespread use of these methods during chemotherapy administration, we think that some more tools are needed to prevent cardiac toxicity in high-risk patients and some of what we studied may deserve further valuation in chemotherapy clinical trials.

关键词： Cardio-Toxicity Diagnostic

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Systemic therapies for hepatocellular carcinoma: arecap of the current status

引用

Hepatoma Research 2018年第4期4卷 1-13页

作者： Petros Giovanis Manuela De Bona Fabio Farinati Andrea Buda Riccardo Berletti fable zustovich Simona D'Ippolito Michele De Boni Umberto Cillo Davide Pastorelli Operative Unit of Medical Oncology Santa Maria del Prato HospitalFeltre 32032Italy Department of Gastroenterology and Digestive Endoscopy Santa Maria del Prato HospitalFeltre 32032Italy Department of Surgery University of PaduaPadua 35128Italy Operative Unit of Radiology and Interventional Radiology Santa Maria del Prato HospitalFeltre 32032Italy Operative Unit of Medical Oncology San Martino HospitalBelluno 32100Italy

After decades of frustrating nihilism due to lack of innovative therapeutic solutions, the onco-hepatological community is facing up to important novelties for the treatment of intermediate and advanced stages of liver cancer. Four new drugs have been investigated and resulted in positive data: lenvatinib resulted not inferior to the standard of care sorafenib in first line, regorafenib and cabozantinib demonstrated prolonging survival in patients progressed to sorafenib and nivolumab approved by FDA as option after first-line. Contemporary, the knowledge acquired after ten years' experience of sorafenib in patient selection and adverse events management revealed an increase of the outcomes. Physicians dedicated to treat advanced and intermediated liver cancer are close to live a new era where systemic treatments could have a huge impact on the disease. The aim of this review is to anticipate this new approach at the disease, summarizing data currently available for these therapies to identify therapeutic strategies of sequences and choosing drugs according to the patient profile.

关键词： Hepatocellular carcinoma liver cancer sorafenib regorafenib lenvatinib cabozantinib nivolumab

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：